Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes

Neuropathology and Applied Neurobiology

Volumn 26, Issue 4, 2000, Pages 347-355

  Chen, C P L H ^a   Eastwood, S L ^b   Hope, T ^d   McDonald, B ^b   Francis, P T ^c   Esiri, M M ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b RADCLIFFE INFIRMARY   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d NONE

Author keywords

Alzheimer's disease; Behavioural changes; Immunocytochemistry; Neuropathology; Raphe nuclei; Serotonin

Indexed keywords

SEROTONIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; BRAIN NERVE CELL; CELL DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRONTAL LOBE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; NERVE CELL PLASTICITY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PRIORITY JOURNAL; RAPHE NUCLEUS; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; BEHAVIORAL SYMPTOMS; CELL COUNT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEURONS; NEUROPIL; PROSPECTIVE STUDIES; RAPHE NUCLEI; SENILE PLAQUES; TAU PROTEINS;

EID: 0033862484     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2990.2000.00254.x     Document Type: Article

References (49)

1. 1 Aletrino MA, Vogels OJM, Van Domburg PHMF, Ten Donkelaar HJ. Cell loss in the nucleus raphes dorsalis in Alzheimer's disease. Neurobiol Aging 1992; 13: 461-8
2. 2 Arendt T, Bigl V, Tennstedt A, Arendt A. Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer's disease. Neuroscience 1985; 14: 1-14
3. 3 Azmitia EC, Whitaker-Azmitia PM. Anatomy, cell biology and plasticity of the serotonergic system. In Psychopharmacology: the Fourth Generation of Progress Eds. FE Bloom, DJ Kupfer. New York: Raven Press, 1995: 443-9
4. 4 Baker KG, Halliday GM, Halasz P et al. Cytoarchitecture of serotonin-synthesizing neurons in the pontine tegmentum of the human brain. Synapse 1990; 7: 301-20
5. 5 Baker KG, Halliday GM, Harnung P, Geffen LB, Cotton RGH, Törk I. Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus. Neuroscience 1990; 42: 757-75
6. 6 Chan-Palay V, Asan E. Alterations in catecholaminergic neurons of the locus coeruleus in senile dementia of the Alzheimer's type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 1989; 287: 373-92
7. 7 Chen CPL-H, Eastwood SL, McDonald B, Esiri MM. Patterns of cell loss and markers for Alzheimer's disease in the dorsal raphe nucleus. Neuropathol Appl Neurobiol 1994; 20: 503
8. 2A receptors is associated with anxiety. Abs Ann Neurol 1994; 36: 308-9
9. 9 Chen CPL-H, Alder JT, Bowen DM et al. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J Neurochem 1996; 66: 1592-8
10. 10 Chenoweth B, Spencer B. Dementia: the experience of family care givers. Gerontologist 1986; 26: 267-72
11. 11 Cotton RGH, McAdam W, Jennings I, Morgan FJ. A monoclonal antibody to aromatic amino acid hydroxylases. Identification of epitopes. Biochem J 1988; 255: 193-6
12. 12 Curcio CA, Kemper T. Nucleus raphe dorsalis in dementia of the Alzheimer's type: neurofibrillary changes and neuronal packing density. J Neuropathol Exp Neurol 1984; 43: 359-68
13. 13 Förstl H, Burns A, Luthert P, Cairns N, Lantos P, Levy R. Clinical and neuropathological correlates of depression in Alzheimer's disease. Psychol Med 1992; 22: 877-84
14. 14 German DC, White CL, Sparkman DR. Alzheimer's disease: neurofibrillary tangles in nuclei that project to cerebral cortex. Neuroscience 1987; 21: 305-12
15. 15 Haan EA, Jennings IG, Cuello AC et al. A monoclonal antibody recognizing all three aromatic amine acid hydroxylases allows identification of serotonergic neurons in human brain. Brain Res 1987; 426: 19-27
16. 16 Halliday GM, Blumbergs PC, Cotton RGH, Blessing WW, Geffen LB. Loss of brain stem serotonin - and substance P-containing neurons in Parkinson's disease. Brain Res 1990; 510: 104-7
17. 17 Halliday GM, Li YW, Blumbergs PC et al. Neuropathology of immunohistochemically identified brain stem neurons in Parkinson's disease. Ann Neurol 1990; 27: 373-85
18. 18 Halliday GM, McCann HL, Pamphlett R et al. Brain stem serotonin-synthesizing neurons in Alzheimer's disease: a clinicopathological correlation. Acta Neuropathol 1992; 84: 638-50
19. 19 Hirano A, Zimmerman HM. Alzheimer's neurofibrillary changes; a topographic study. Arch Neurol 1962; 7: 227-41
20. 20 Francis P, Webster M, Chessell I et al. Neurotransmitters and second messengers in aging and Alzheimer's disease. Ann NY Acad Sci (USA) 1993; 695: 19-26
21. 21 Holmes C, Russ C, Kirov G et al. Apolipoprotein E. depressive illness, depressive symptoms and Alzheimer's disease. Biol Psychiat 1998; 43: 159-64
22. 22 Hope T, Fairburn CG. The Present Behavioural Examination (PBE): the development of an interview to measure current behavioural abnormalities. Psychol Med 1992; 22: 223-30
23. 23 Hope T, Keene J, Gedling K, Cooper S, Fairburn C, Jacoby R. Behaviour changes in dementia 1: point of entry data of a prospective study. Int J Geriatr Psych 1997; 12: 1062-73
24. 24 Hope T, Keene J, Fairburn CG, McShane R, Jacoby R. Behaviour changes in dementia 2: are there behavioural syndromes? Int J Geriatr Psych 1997; 12: 1074-8
25. 25 Ishii T. Distribution of Alzheimer's neurofibrillary changes in the brain stem and hypothalamus of senile dementia. Acta Neuropathol 1966; 6: 181-7
26. 26 Khachatarian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42: 1097-104
27. 27 Leake A, Moore PB, Leitch M et al. The serotonergic system in Alzheimer's disease and normal neocortical post mortem brain: neurochemical and clinical correlates. Neurol Psychiat Brain Res 1993; 2: 53-9
28. 28 Mann DMA, Yates PO. Serotonin nerve cells in Alzheimer's disease. J Neurol Neurosurg Psychiat 1983; 46: 96-8
29. 29 Mann DMA, Yates PO, Marcyniuk B. Monoaminergic neurotransmitter systems in presenile Alzheimer's disease and in senile dementia of Alzheimer type. Clin Neuropathol 1984; 3: 199-205
30. 30 Mann DMA, Yates PO, Marcyniuk B. Correlation between senile plaque and neurofibrillary tangle counts in cerebral cortex and neuronal counts in cortex and subcortical structures in Alzheimer's disease. Neurosci Lett 1985; 56: 51-5
31. 31 Margo JL, Robinson JR, Corea S. Referrals to a psychiatric service from old peoples' homes. Brit J Psychiat 1980; 136: 396-401
32. 32 Mirra SS, Heyman A, McKeel D et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardisation of the neuro-pathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-86
33. 33 Medical Research Council Report from the MRC. Alzheimer's Disease Workshop, 1987
34. 34 Poirier J, Delisle M-C, Quirion R et al. Apolipoprotein E 4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci (USA) 1995; 92: 12260-4
35. 35 Procter AW, Francis PT, Stratmann GC, Bowen DM. Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms. Neurochem Res 1992; 17: 917-22
36. 36 Ramachandran G, Marder K, Tang M et al. A preliminary study of apoliproprotein E genotype and psychiatric manifestations of Alzheimer's disease. Neurology 1996; 47: 256-9
37. 37 Sanford JRA. Tolerance of debility in elderly dependants by supporters at home: its significance for hospital practice. Brit Med J 1975; 3: 471-3
38. 38 Sofroniew MV, Pearson RG, Powell TP. The cholinergic nuclei of the basal forebrain of the rat: normal structure development and experimentally induced degeneration. Brain Res 1987; 411: 310-31
39. 39 Sofroniew MV, Isacson O. Distribution of degeneration of cholinergic neurons in the septum following axotomy in different portions of the fimbria-fornix: a correlation between degree of cell loss and proximity of neuronal somata to the lesion. J Chem Neuroanat 1988; 1: 327-37
40. 40 Soininen H, Kosunen O, Helisalmi S et al. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein e4 allele. Neurosci Lett 1995; 187: 79-82
41. 41 Steele C, Rouner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Amer J Psychiat 1990; 147: 1049-51
42. 42 Tabaton M, Schenone A, Romagnoli P, Mancardi GL. A quantitative and ultrastructural study of substantia nigra and nucleus centralis superior in Alzheimer's disease. Acta Neuropathol 1985; 68: 218-23
43. 43 Törk T, Hornung J-P. Raphe nuclei and the serotonergic system. In: The Human Nervous System Ed. G. Paxinos San Diego: Academic Press, 1990: 1002-22
44. 44 Vogels OJ, Broere CA, ter Laak HJ et al. Cell loss and shrinkage in the nucleus basalis of Meynert complex in Alzheimer's disease. Neurobiol Aging 1990; 11: 3-13
45. 45 West MJ, Gundersen HJG. Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 1990; 296: 1-22
46. 46 Wilcock GK, Esiri MM, Bowen DM, Smith CCT. The nucleus basalis in Alzheimer's disease: a correlation between cell counts, cortical biochemistry and histology. Neuropathol Appl Neurobiol 1983; 9: 175-9
47. 47 Wilcock GK, Esiri MM, Bowen DM, Hughes AO. The differential involvement of subcortical nuclei in senile dementia of Alzheimer type. J Neurol Neurosurg Psychiat 1988; 51: 842-9
48. 48 Yamamoto T, Hirano A. Nucleus raphe dorsalis in Alzheimer's disease: neurofibrillary tangles and loss of large neurons. Ann Neurol 1985; 17: 573
49. 49 Zweig RM, Ross CA, Hedreen JC et al. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 1988; 24: 233-42